Key Points
- Endurance (Cayman) Ltd Svf sold 191,854 shares of Vir Biotechnology on Dec. 1 at an average price of $5.98 for $1.147M, cutting its stake to 13,728,924 shares (a 1.38% decrease) — part of a string of sizable insider sales across late October and November.
- Vir's stock recently opened at $6.27 with a market cap of about $872.3M, the company reported materially negative earnings (missed estimates) and analysts hold a consensus "Moderate Buy" with a $17.30 price target.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of Vir Biotechnology stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.98, for a total transaction of $1,147,286.92. Following the sale, the insider directly owned 13,728,924 shares of the company's stock, valued at $82,098,965.52. This represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Endurance (Cayman) Ltd Svf also recently made the following trade(s):
- On Friday, November 28th, Endurance (Cayman) Ltd Svf sold 61,493 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.44, for a total value of $396,014.92.
- On Wednesday, November 26th, Endurance (Cayman) Ltd Svf sold 127,938 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.39, for a total value of $817,523.82.
- On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.38, for a total value of $1,505,494.98.
- On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $1,400,988.45.
- On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total value of $649.00.
- On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.50, for a total value of $158,944.50.
- On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $401,738.15.
- On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.96, for a total transaction of $278,308.16.
- On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total transaction of $924,754.17.
- On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total transaction of $887,235.90.
Vir Biotechnology Stock Up 11.4%
VIR opened at $6.27 on Thursday. The stock has a market cap of $872.31 million, a P/E ratio of -1.74 and a beta of 1.34. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45. The company has a fifty day simple moving average of $5.80 and a 200 day simple moving average of $5.33.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the firm posted ($1.56) earnings per share. The business's revenue was up .8% on a year-over-year basis. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Institutional Trading of Vir Biotechnology
Institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in Vir Biotechnology in the second quarter valued at $35,000. Federated Hermes Inc. boosted its stake in shares of Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock worth $46,000 after buying an additional 4,899 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $50,000. Daiwa Securities Group Inc. grew its holdings in shares of Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock valued at $62,000 after acquiring an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Vir Biotechnology in the second quarter valued at about $63,000. Institutional investors own 65.32% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research report on Monday, September 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Vir Biotechnology in a research note on Monday. Evercore ISI initiated coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $12.00 price target for the company. Finally, Bank of America upgraded shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.30.
Read Our Latest Research Report on VIR
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
